Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749203 · ClinicalTrials.gov registry record · Phase 2
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
A Phase 2 study of Depression and PTSD, sponsored by Dennis Charney.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00749203: Completed Phase 2 study of Depression and PTSD, sponsored by Dennis Charney.
NCT00749203 is a Phase 2 study of Depression and PTSD that has completed, run by Dennis Charney. The registered enrollment target is 41 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00749203, a Phase 2 study of Depression and PTSD, has completed, sponsored by Dennis Charney.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
Primary Outcome
A 22-item self-report questionnaire measuring PTSD symptoms. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score ranging from 0 (not at all) to 88 (extremely)
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Midazolam
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT00749203 record still lists
NCT00749203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT00749203 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00749203 about?
NCT00749203 is a clinical study titled "Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)". The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
What is the current status of trial NCT00749203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2009-01. Estimated completion is 2013-09.
What conditions does trial NCT00749203 study?
This clinical trial studies the following conditions: Depression, PTSD, Stress Disorders, Post-Traumatic, Anxiety Disorder.
What interventions are being tested in trial NCT00749203?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT00749203?
This trial is sponsored by Dennis Charney, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00749203 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00749203's enrollment target sits among peer trials
41 506th of 679 higher than 172 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia